ErbB2 _ HER2 Antibody
- Known as:
- ErbB2 _ HER2 Antibody
- Catalog number:
- 10004-RP03
- Product Quantity:
- 200
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- ErbB2 _ HER2 Antibody
Related genes to: ErbB2 _ HER2 Antibody
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: ErbB2 _ HER2 Antibody
Related articles to: ErbB2 _ HER2 Antibody
- Pancreatic cancer (PC) is a devastating disease with high mortality and a pressing need for safer, less toxic therapies. This study identifies Hui-Xiang decoction (HXD), a formulation from food and medicine homology (FMH) herbs, as an effective and low-toxicity treatment. We identified the presence of 122 active ingredients and 12 PC associated targets in HXD by network pharmacology. HXD and its active component, ammidin, effectively inhibited the proliferation and migration of PC cells. Furthermore, treatment with HXD in clinically relevant patient-derived organoid (PDO) and xenograft (PDX) models significantly inhibited tumor growth, with minimal toxicity. Crucially, we found that HXD combats PC through a dual mechanism: simultaneously inhibiting the oncogenic EGFR/ErbB2/AKT1 pathway and activating the tumor-suppressive Hippo signaling pathway. These results not only elucidate the molecular basis for HXD's efficacy but also provide a strong rationale for its potential application in the management of PC. - Source: PubMed
Zhang JianTang NannanGu AoLi JiatongLi Meng-Yao - Current daily usage of Trastuzumab Deruxtecan (T-DXd) is guided by immunohistochemistry (IHC)-based HER2 assessment, with known inconsistency and inaccuracy to differentiating IHC 0 from 1 +. In this study, a quantitative HER2 assay based on the Quantitative Dot Blot (QDB) method was explored to fill this unmet need. - Source: PubMed
Publication date: 2026/04/27
Hao JunmeiFei XiaochunZou FangfangHu QianDu LinlinYu LiyaBai XuanyeBi ShashaCao QinghuaChen WeishanDai QunGuo TingtingHuang HaiJiang WenweiLi BaohuaLi LixiaLiu JingjingLiu TongLiu XiaoqinLyu JiahongPan YueShao XiaoqingTang FangrongWang TingtingZhang CuipingZhu YongcunLiu Job Tien ChiangSalazar NicoleZhang ShukunZhang JiandiChen XiaosongWang Chaofu - Trastuzumab deruxtecan is a newly developed antibody-drug conjugate (ADC) designed to overcome human epidermal growth factor receptor 2 (HER2) aberrations. Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a manageable safety profile in previously treated non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. However, data on efficacy of Trastuzumab deruxtecan for acquired HER2-amplified NSCLC are limited. Here, we report a case of a patient with metastatic lung adenocarcinoma who developed acquired high-level HER2 amplification (20 copies) after 2nd-line Osimertinib. A partial response (PR) was achieved with reduced-dose Trastuzumab deruxtecan. Plasma next-generation sequencing (NGS) further confirmed successful inhibition of HER2 amplification.
. - Source: PubMed
Ge XiaoxiaoChen HefengCui Shaohua - The biologic and prognostic value of tumor human epidermal growth factor receptor 2 (HER2) expression in patients with advanced urothelial carcinoma (UC) who undergo systemic therapies remains controversial. A systematic search of English-language literature using PubMed, Scopus, and Cochrane Library was performed in October 2025 according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) protocol to evaluate the prognostic value of tumor HER2 expression in predicting oncological outcomes of patients with advanced UC. The primary endpoints were recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). Seventeen studies comprising 4909 patients were eligible. HER2 expression was significantly associated with inferior RFS (HR 1.68, 95% CI 1.16-2.42; = 0.005) and CSS (HR 1.36, 95% CI 1.10-1.68; = 0.004), but not with OS (HR 1.03, 95% CI 0.54-1.80) or PFS (HR 0.97, 95% CI 0.50-1.89), in patients with advanced UC. In conclusion, tumor HER2 expression may identify a subgroup of patients with advanced UC at increased risk of recurrence and cancer-specific mortality, supporting its potential role as a prognostic biomarker. However, standardized assessment and prospective studies are warranted to define its utility for risk stratification and therapeutic targeting. - Source: PubMed
Publication date: 2026/05/05
Alibeiginejad Mohammad HosseinEsmaielpour AlirezaTsuboi IchiroMatsukawa AkihiroYanagisawa TakafumiMori KeiichiroKardoust Parizi Mehdi - : A unique group of non-small cell lung cancer (NSCLC) is driven by alterations in HER2. Early studies, mostly from advanced NSCLC, suggest that NSCLC with HER2 alterations confers a poor prognosis. However, modern studies are scant. : We performed an analysis of a United States-based database on stage I-III NSCLC patients diagnosed during 2019-2024. Cases with complete data on EGFR, ALK, and HER 2 alterations were included. Study cohorts were divided into: EGFR or ALK alterations (EGFR/ALK group), HER2 alterations (HER2 group), or negative for these alterations (triple-negative group). Outcomes of interest were survival. : Analyses were performed on data from 3486 patients: 515 patients (15%) in the EGFR/ALK group, 173 patients (5%) in the HER2 group, and 2798 patients (80%) in the triple-negative group. Median disease-free survival (DFS) was 41.3 months, 26.6 months, and 21.2 months, respectively. Median overall survival (OS) was 62.5 months, 63.7 months, and 40.1 months, respectively. Multivariable analysis showed that DFS and OS were significantly worse among the triple-negative group than HER2 group: adjusted HRs 1.44 (95% CI: 1.08-1.90, = 0.01) and 1.94 (95% CI: 1.25-3.01, = 0.003), respectively. In the subgroup of patients with HER2 alterations, no significant difference in DFS or OS was found among patients with HER2 mutation, HER2 amplification, or HER2 overexpression in this exploratory analysis. : When classified by the status of EGFR, ALK and HER2, early-stage NSCLC patients with HER2 alterations had significantly better DFS and OS than those with triple-negative biomarkers. - Source: PubMed
Publication date: 2026/05/01
Tanvetyanon TaweeChen Dung-TsaGray Jhanelle E